Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review.

about

Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review.

Item

http://www.wikidata.org/entity/Q48145007

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Reporting of health-related qu ...... c cancer: a systematic review.

@en

Reporting of health-related qu ...... c cancer: a systematic review.

@nl

type

Item

label

Reporting of health-related qu ...... c cancer: a systematic review.

@en

Reporting of health-related qu ...... c cancer: a systematic review.

@nl

prefLabel

Reporting of health-related qu ...... c cancer: a systematic review.

@en

Reporting of health-related qu ...... c cancer: a systematic review.

@nl

P1476

Reporting of health-related qu ...... ic cancer: a systematic review

@en

P2093

Emil Ter Veer

http://www.w3.org/2001/XMLSchema#string

Martijn G H van Oijen

http://www.w3.org/2001/XMLSchema#string

Mirjam A G Sprangers

http://www.w3.org/2001/XMLSchema#string

Nadia Haj Mohammad

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Chemotherapy for advanced gastric cancer

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Global cancer statistics, 2012

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

P2888

s10120-018-0792-3

P304

183-195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-018-0792-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hanneke Wm van Laarhoven

Jessy Joy van Kleef

P5008

ScienceSource

P577

2018-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29380191

http://www.w3.org/2001/XMLSchema#string

P921

biomedical investigative technique

P932

5846827

http://www.w3.org/2001/XMLSchema#string